Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743946 · ClinicalTrials.gov registry record · Phase 4
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05743946: Completed Phase 4 study, sponsored by Emory University.
NCT05743946 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 32 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743946, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.
Primary Outcome
In vitro responsiveness to Trikafta is tested by determining if iPS cells that are differentiated to airway epithelia and treated with Trikafta display functional correction of CFTR expression. This is assessed by measuring short circuit currents in monolayers.
Interventions
- DRUG Trikafta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 4 |
What the finished NCT05743946 record still lists
NCT05743946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Trikafta is the first listed.
NCT05743946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05743946 about?
NCT05743946 is a clinical study titled "Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis". Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test...
What is the current status of trial NCT05743946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2023-04-18. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT05743946?
The interventions under investigation include: Trikafta (DRUG).
Who is sponsoring clinical trial NCT05743946?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05743946's enrollment target sits among peer trials
32 1534th of 2000 higher than 457 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI